Puma Biotechnology Report Induction Award under Nasdaq Listing Rules 5635(c)(4)


Puma Biotechnology Company (NASDAQ:PBYI), a biopharmaceutical company, announced that on June 2, 2021, the Remuneration Committee of the Puma Board of Directors approved the award of incentive restricted stock unit awards to five new non-executive employees, totaling 30,375 shares of Puma common stock.

The award was awarded under Puma’s 2017 Employment Incentive Award Program, which was passed on April 27, 2017, and stipulates that Puma’s new employees will be granted equity awards. The award period for restricted stock unit awards is three years. One-third of each award is awarded on the first anniversary of the award start date (ie June 1, 2021) and one-sixth of each award is granted in its Each 6-month anniversary of the vesting start date after the vesting date, subject to continued service. According to Article 5635(c)(4) of the Nasdaq Listing Rules, these rewards are used as incentive materials for new employees to work at Puma.

About Puma Biotech

Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative products to enhance cancer care. Puma has obtained the global development and commercialization rights for PB272 (lenatinib, oral), PB272 (lenatinib, intravenous injection) and PB357. Oral lenatinib was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of early HER2 overexpression/amplification breast cancer patients after receiving trastuzumab-based adjuvant therapy. And it is marketed as NERLYNX ® (neratinib) tablets in the United States. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer. These patients have received two or more anti-HER2-based drugs in a metastatic setting. Plan. NERLYNX was approved by the European Commission in 2018 to expand the adjuvant treatment of adult patients with early hormone receptor-positive HER2 overexpression/amplification of breast cancer. These patients are not close to the previous trastuzumab-based adjuvant therapy. To one year. NERLYNX is a registered trademark of Puma Biotechnology, Inc.



Source link

Recommended For You

About the Author: Brand Story